A review of valproic acid-induced carnitine deficiency and replacement

Journal of Pharmacy Technology

Volumn 17, Issue 3, 2001, Pages 81-83

  Ahluwalia, Navneet S ^a   Bernad, Peter G ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; VALPROIC ACID;

ANTICONVULSANT THERAPY; CARNITINE DEFICIENCY; DRUG INDUCED DISEASE; DRUG OVERDOSE; HUMAN; LIVER TOXICITY; METABOLISM; REVIEW; TREATMENT INDICATION;

EID: 0035018634     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250101700301     Document Type: Review

References (11)

1. Raskind J, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000;34:630-8.
2. Eadie MJ, Tyrer JH. Anticonvulsant therapy: pharmacologic basis and practice, 3rd ed. New York: Churchill Livingstone, 1989.
3. Drugs for psychiatric disorders. Med Lett Drug Ther 1997;39:33-40.
4. Bernad PG Neurotoxicology: a clinical source book. Charlottesville, VA: Lexis Law Publishers, 1998.
5. Pons R, DeVivo DC. Primary and secondary carnitine deficiency syndromes. J Child Neurol 1995;10(suppl 2):S8-24.
6. Schmidt-Sommerfield E, Werner D, Penn D. Carnitine plasma concentrations in 353 metabolically healthy children. Eur J Pediatr 1988; 147:356-60.
7. McCurdy HT. Carnitine deficiency Pediatrics 1995,96:1174-5.
8. Baynes J, Dominczak M. Medical biochemistry. New York: Mosby, 1999.
9. Engel A, Franzini-Armstrong C. Myology: basic and clinical. 2nd ed. New York: McGraw-Hill, 1994.
10. Kelley RI. The role of carnitine supplementation in valproic acid therapy. Pediatrics 1994;93(6 pt 1):891-2.
11. Freeman JM, Vining EP, Cost S, Singhi P. Does carnitine administration improve the symptoms attributed to anticonvulsant medications?: a double-blinded, crossover study Pediatrics 1994;93(6 pt 1):893-5.